Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

51.10 +0.11 (+0.22%)
Streaming Delayed Price Updated: 12:27 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceu

< Previous 1 2 3 4 5 6 7 8 Next >
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Ultragenyx Pharmaceutical's Return On Capital Employed Insights
Via Benzinga
Ultragenyx Pharmaceutical: Q1 Earnings Insights
Via Benzinga
A Preview Of Ultragenyx Pharmaceutical's Earnings
Via Benzinga
Expert Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
Amended U.S. protocol increases loading and maintenance doses to similar range as ex-U.S. expansion cohorts 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
Oral presentations include longer term durability data from DTX301 and DTX401 and showcase the Pinnacle PCL™ (AAV vector producer cell line) platform and technology 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Where Ultragenyx Pharmaceutical Stands With Analysts
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview: Ultragenyx Pharmaceutical
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
Via Benzinga
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2023
Via Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.